pSivida Corp. Announces Second Quarter 2013 Financial Results Release Date and Conference Call Information

  pSivida Corp. Announces Second Quarter 2013 Financial Results Release Date
  and Conference Call Information

Business Wire

WATERTOWN, Mass. -- January 30, 2013

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye diseases,
today announced that its financial results for the second quarter of fiscal
year 2013 will be released after the market close on Wednesday, February 6,
2013, followed the same day by a conference call and live webcast scheduled
for 4:30 p.m. ET.

The conference call may be accessed by dialing (877) 303-9236 from the U.S.
and Canada, or (760) 666-3569 from international locations. A live webcast
will be available on the Investor Relations section of the corporate website
at http://www.psivida.com.

A replay of the call will be available beginning February 6, 2013 at
approximately 7:30 p.m. ET and ending on February 13, 2012. The replay may be
accessed by dialing (855) 859-2056 within the U.S. and Canada or (404)
537-3406 from international locations, Conference ID Number: 95328173. A
replay of the webcast will also be available on the corporate website during
that time.

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a controlled and
steady rate for months or years. pSivida is currently focused on treatment of
chronic diseases of the back of the eye utilizing its core technology systems,
Durasert™ and BioSilicon™. The injectable, sustained release micro-insert
ILUVIEN® for the treatment of chronic Diabetic Macular Edema (DME), licensed
to Alimera Sciences, Inc., has received marketing authorization in Austria,
France, Germany, Portugal, the U.K. and Spain, and is awaiting authorization
in Italy. The United States Food and Drug Administration (FDA) has cleared
pSivida's Investigational New Drug application (IND) to treat posterior
uveitis with the same micro-insert. An investigator-sponsored clinical trial
is ongoing for an injectable, bioerodible insert to treat glaucoma and ocular
hypertension. pSivida's two FDA-approved products, Retisert® and Vitrasert®,
are implants that provide long-term, sustained drug delivery to treat two
other chronic diseases of the retina.

For more information on pSivida, visit www.psivida.com.

Contact:

In US:
Martin E. Janis & Company, Inc.
Beverly Jedynak
President
Tel: +1 (312) 943 1123
bjedynak@janispr.com
or
In Australia:
pSivida Corp.
Brian Leedman
Vice President, Investor Relations
+61 (0) 41 228 1780
brianl@psivida.com
 
Press spacebar to pause and continue. Press esc to stop.